Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciprofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.96 |
| ▸ | LMNA | P02545 | 5/20 | 0.96 |
| ▸ | HPGD | P15428 | 4/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | TOP2A | P11388 | 1/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciprofloxacin SCHEMBL1281819 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2325952 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL184706 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL27004 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL8530004 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL23064249 | 1.00 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2465661 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL42310 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL7994990 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL9788110 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1429780-B1 | METHOD OF TREATING MIDDLE EAR INFECTIONS | ALCON INC (CH) | 2005-12-21 | — | — | EP | claimed |
| EP-1214056-B1 | TOPICAL SUSPENSION FORMULATIONS CONTAINING CIPROFLOXACIN AND DEXAMETHASONE | ALCON INC (CH) | 2003-10-29 | — | — | EP | claimed |
| EP-4294521-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | Cap Diagnostics, LLC, DBA Pathnostics (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230392185-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | CAP Diagnostics, LLC, dba Pathnostics | 2023-12-07 | — | — | US | disclosed |
| US-20230357818-A1 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | CAP Diagnostics, LLC, dba Pathnostics | 2023-11-09 | — | — | US | disclosed |
| US-20230357817-A1 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | CAP Diagnostics, LLC, dba Pathnostics | 2023-11-09 | — | — | US | disclosed |
| US-11746371-B2 | Methods for treating polymicrobial infections | CAP Diagnostics, LLC (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220411782-A1 | PHAGE COMPOSITIONS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | Locus Biosciences, Inc. | 2022-12-29 | — | — | US | disclosed |
| US-20220315975-A1 | METHODS AND SYSTEMS FOR PREPARING THERAPEUTIC SOLUTIONS FOR POLYMICROBIAL INFECTIONS | BANK OF HOPE | 2022-10-06 | — | — | US | disclosed |
| WO-2022178142-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | CAP Diagnostics, LLC, dba Pathnostics (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2021211746-A1 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | CAP Diagnostics, LLC, dba Pathnostics (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2004089418-A1 | A FLUOROQUINOLONE AQUEOUS FORMULATION OF A PH BETWEEN 4 AND 7 COMPRISING I.A. CYCLODEXTRIN, HYDROXYACID | DSM IP ASSETS B.V. (NL) | 2004-10-21 | — | — | WO | disclosed |
| US-20040202687-A1 | Ciprofloxacin formulations and methods of making and using the same | DSM IP ASSETS B.V. (NL) | 2004-10-14 | — | — | US | disclosed |
| US-6221386-B1 | THERAPEUTIC AGENT ENTRAPPED WITHIN A LIPOSOME COMPRISING A SMOOTH LIPOPOLYSACCHARIDE FROM BRUCELLA MELITENSIS. | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 2001-04-24 | — | — | US | disclosed |
| US-5827895-A | INHIBITING THE INFECTION OF STAPHYLOCOCCUS OR MYCOBACTERIUM BY ADMINISTERING A CYCLOHEXANE-DIKETONE-DIOLS; ANTICARCINOGENIC AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-10-27 | — | — | US | disclosed |
| WO-1998011883-A1 | USE OF HEXAHYDROLUPULONES AS ANTIBACTERIAL AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-03-26 | — | — | WO | disclosed |
| US-5409898-A | Synergistic composition containing beta-lactam antibiotic and cationic polypeptide | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0516747-A4 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS CAUSED BY ORGANISMS SENSITIVE TO -G(B)-LACTAM ANTIBIOTICS | — | 1993-03-24 | — | — | EP | disclosed |
| EP-0516747-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS CAUSED BY ORGANISMS SENSITIVE TO $g(b)-LACTAM ANTIBIOTICS | Bristol-Myers Squibb Company (US) | 1992-12-09 | — | — | EP | disclosed |
| WO-1991012815-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS CAUSED BY ORGANISMS SENSITIVE TO β-LACTAM ANTIBIOTICS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040202687-A1 | Ciprofloxacin formulations and methods of making and using the same | CYP2D6, CYP8B1, CHCHD6 | KDM4E 3830/4885ALDH1A1 2533/4885LMNA 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.